С.Сээсрэгдорж
Loading...
Товч нэр
С.Сээсрэгдорж
Бүтэн нэр
Сүрэнжид Сээсрэгдорж
Латин нэр
Surenjid Seesregdorj
Албан тушаал
Гэрээт багш
Боловсролын зэрэг
Доктор (Ph.D)
Харьяалал
ORCID
4 results
Now showing 1 - 4 of 4
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Dehydrocostus Lactone Down - regulates Lipopolysaccharide-induced SAA3 gene activation in the Microglia.(Mongolian National University of Medical Sciences, 2023-12-16) ;Fuquan, Zhao; ; ; Running Title: DDL inhibits the LPS-induced SAA3 gene expression in microgliaObjective: Research on the mechanism of Dehydrocostus lactone (DDL) in microglial cells of the brain needs to be improved, despite its reported anti-inflammatory, anticancer, and anti-proliferation properties as a natural product of Eerdun Wurile The precise functions of the Serum amyloid A (SAA) genes are not yet defined. However, these genes are suggested to possess antibacterial properties and can attract monocytes and neutrophils. On the other hand, SAA genes can also induce inflammatory cytokines and metalloproteinases in smooth muscle cells and macrophages, thus promoting inflammation. This study aimed to investigate the impact of DDL on SAA3 gene expression in microglial cells stimulated by LPS.Methods: The anti-inflammatory effects of DDL were studied using LPS-stimulated murine BV2 microglia. BV2 was cultured in DMEM, and then 4µM DDL was added. Then BV2 was treated with one ng/ml LPS for 24 hours to stimulate. Results: LPS treatment increased the expression of SAA3 mRNA in BV2 microglial cells, while DDL pre-treatment inhibited LPS-induced SAA3 mRNA expression.Conclusion: Microglia cells treated with LPS display a significant reduction in the expression of SAA3 gene transcripts upon treatment with DDL. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Dehydrocostus Lactone Inhibits the Expression of Inducible Slfn-4 in LPS-Activated Microglia(Mongolian National University of Medical Sciences, 2021-04-01) ;Fuquan, Zhao; ; ; Objectives: Dehydrocostus lactone (DDL) natural product of Eerdun Wurile that has been reported to have anti-inflammatory, anticancer, and anti-proliferation effect. However, no research has been done regarding mechanism of DDL on microglial cells in the brain. Moreover, Schlafen (Slfn) genes are considered to play important regulatory roles for normal cell growth and differentiation of the immune and hematopoietic systems. Among schlafen genes, Slfn-4 is much modulated during macrophage stimulation and differentiation and implicates macrophage in responses to pathogens. The present study was conducted to investigate effects of DDL on Slfn-4 gene expression in lipopolysaccharide (LPS)-stimulated microglial cells. Methods: The anti-inflammatory effects of DDL were studied using LPS-stimulated murine BV2 microglia. BV2 were cultured in DMEM then 4pM DDL were added. Then BV2 was treated with 1 ng/ml LPS for 24 hours to stimulate. Results: LPS alone increased Slfn-4 mRNA expression in BV2 microglial cells (p < 0.01). In contrast, DDL pre-treatment significantly inhibited LPS-induced Slfn-4 mRNA expression (p < 0.05). Conclusions: DDL inhibits the expression of Slfn-4 gene transcripts related with inflammation, activated by LPS in the microglia cells. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Микроглий эсэд дегидрокостус лактоны үрэвслийн эсрэг нөлөөг CXCL2 генийн идэвхижлээр тодорхойлсон дүн(2021-11-01) ;Zhao Fuquan; ; Монгол анагаах ухаанд “Саа өвчин”-д хэрэглэдэг Эрдэнийн үрлийн найрлагад ордог дегидрокостус лактоны үйлдлийн механизм одоог хүртэл бүрэн судлагдаагүй байна. Хемокин СХС лиганд 2 (CXCL2) нь макрофагаас ялгарч эсийн гадаргуу дахь СХСR2 хүлээн авууртай холбогдож эсийг хөдөлгөөнтэй болгож үрэвслийн процессыг дэмжих, дархлаа зохицуулах зэрэг үйл ажиллагаанд оролцдог. Микроглий эсийн CXCL2 ба дегидрокостус лактоны харилцан үйлчлэлийг судлах нь эмчилгээний чухал ач холбогдолтой юм. Зорилго: Микроглий эсэд дегидрокостус лактоны үрэвслийн эсрэг нөлөөг CXCL2 генийн идэвхижлээр тодорхойлох. Арга, аргачлал: Хулганын тархинаас гарган авсан BV2 микроглий эсийг 1. Дангаар нь, 2. Липополисахаридыг нэмсэн байдлаар, 3. Дегидрокостус лактоныг нэмж дараа нь липополисахаридыг нэмсэн гурван хэлбэрээр өсгөвөрлөв. Энэ 3 өөр өсгөврийн микроглий эсээс нийт RNA-г ялган сDNA-г гарган авч бодит хугацааны полимеразийн гинжин урвалын (qRT-PCR) туршилтаар CXCL2-ын генийн экспрессийн түвшинг тодорхойлов. Үр дүн: Микроглий эс тайван үед CXCL2 генийн идэвхжил суурь түвшинд тодорхойлогдов. Харин 1 нг/мл липополисахаридаар үйлчлэхэд CXCL2 генийн мРНХийн түвшин ойролцоогоор 3 дахин нэмэгдэж байв. Дегидрокостус лактон нь липополисахаридаар идэвхжих CXCL2 генийн мРНХ-ийн түвшинг 2.9–өөс 1.9 хүртэл саатуулж байна. Дүгнэлт: Дегидрокостус лактон нь липополисахаридаар идэвхжих микроглий эсийн CXCL2-ын генийн экспрессын түвшинг саатуулах үйлдэлтэй байна. Уламжлалт анагаах ухаанд өргөн хэрэглэгддэг эмийн бодисуудын гол бүрэлдэхүүн болох дегидрокостус лактон нь мэдрэлийн эмгэгийн үед үрэвслийн эсрэг үйлдэлтэй байна. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia(Public Library of Science (PLoS), 2023); ;Otgonbayar, Dashpagma; ; The SARS-CoV-2 vaccination campaign began in February 2021 and achieved a high rate of 62.7% of the total population fully vaccinated by August 16, 2021, in Mongolia. We aimed to assess the initial protective antibody production after two doses of a variety of types of SARS-CoV-2 vaccines in the Mongolian pre-vaccine antibody-naïve adult population. This prospective study was conducted from March-April to July-August of 2021. All participants received one of the four government-proposed COVID-19 vaccines including Pfizer/BioNTech (BNT162b2), AstraZeneca (ChAdOx1-S), Sinopharm (BBIBP-CorV), and Sputnik V (Gam-COVID-Vac). Before receiving the first shot, anti-SARS-CoV-2 S-RBD human IgG titers were measured in all participants (n = 1833), and titers were measured 21-28 days after the second shot in a subset of participants (n = 831). We found an overall average protective antibody response of 84.8% (705 of 831 vaccinated) in 21-28 days after two doses of the four types of COVID-19 vaccines. Seropositivity and titer of protective antibodies produced after two shots of vaccine were associated with the vaccine types, age, and residence of vaccinees. Seropositivity rate varied significantly between vaccine types, 80.0% (28 of 35) for AstraZeneca ChAdOx1-S; 97.0% (193 of 199) for Pfizer BNT162b2; 80.7% (474 of 587) for Sinopharm BBIBP-CorV, and 100.0% (10 of 10) for Sputnik V Gam-COVID-Vac, respectively. Immunocompromised vaccinees with increased risk for developing severe COVID-19 disease had received the Pfizer vaccine and demonstrated a high rate of seropositivity. A high geometric mean titer (GMT) was found in vaccinees who received BNT162b2, while vaccinees who received ChAdOx1-S, Sputnik V, and BBIBP-CorV showed a lower GMT. In summary, we observed first stages of the immunization campaign against COVID-19 in Mongolia have been completed successfully, with a high immunogenicity level achieved among the population with an increased risk for developing severe illness.Scopus© Citations 1
